Buscar resultados de ensayos clínicos
Osteomalacia - 32 Studies Found
Estado | Estudiar |
Recruiting |
Nombre del estudio: 68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia Condición:
Fecha: 2012-01-29 Intervenciones: Drug: 68Ga-DOTATATE Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. T |
Recruiting |
Nombre del estudio: Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors Causing Oncogenic Osteomalacia Condición: Tumor Induced Oncogenic Osteomalacia Fecha: 2015-01-05 |
Active, not recruiting |
Nombre del estudio: A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome Condición: Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome Fecha: 2016-03-07 Intervenciones: Drug: KRN23 Doses may be titrated to achieve the target peak serum phosphorus range |
Active, not recruiting |
Nombre del estudio: Study of KRN23 in Adult Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS) Condición:
|
Recruiting |
Nombre del estudio: Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia Condición: Hypophosphatemia Fecha: 2012-08-05 |
Completed |
Nombre del estudio: Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia Condición:
Fecha: 2004-12-17 |
Terminated |
Nombre del estudio: Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets) Condición: Osteomalacia Fecha: 2012-12-11 Intervenciones: Drug: Osteomalacia |
Recruiting |
Nombre del estudio: 68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia Condición:
Fecha: 2012-01-29 Intervenciones: Drug: 68Ga-DOTATATE Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. T |
Completed |
Nombre del estudio: A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia Condición: X-linked Hypophosphatemic Rickets/Osteomalacia Fecha: 2014-07-02 Intervenciones: Drug: KRN23 Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg |
Active, not recruiting |
Nombre del estudio: A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome Condición: Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome Fecha: 2016-03-07 Intervenciones: Drug: KRN23 Doses may be titrated to achieve the target peak serum phosphorus range |